구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Concurrent chemoradiation (Concurrent chemoradiation) NovoCure Ltd.·Extranodal NK/T-cell Lymphoma, Nas… 60 trials |
|---|---|
Overview Program | Concurrent chemoradiation |
Overview Company | NovoCure Ltd. |
Overview Modality | CGT |
Overview Target | Extranodal NK/T-cell Lymphoma, Nasal Typ |
Overview Indication | Extranodal NK/T-cell Lymphoma, Nasal Type |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen |
MoA Biomarker | biomarkers that complement established staging and Epstein-Barr virus (EBV)-DNA assessment |
PK/PD Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis (10 |
Clinical Safety signal | pneumonitis (10 |
Clinical Selected reported efficacy | ORR 47% |
Clinical Reported ORR | 47% |
Clinical Reported PFS | 8 |
Clinical Reported OS | 14 |
Clinical Result source | ClinicalTrials.gov NCT00288054 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00288054 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Concurrent chemoradiation (Concurrent chemoradiation) NovoCure Ltd.·Extranodal NK/T-cell Lymphoma, Nas… 60 trials |
|---|---|
Overview Program | Concurrent chemoradiation |
Overview Company | NovoCure Ltd. |
Overview Modality | CGT |
Overview Target | Extranodal NK/T-cell Lymphoma, Nasal Typ |
Overview Indication | Extranodal NK/T-cell Lymphoma, Nasal Type |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen |
MoA Biomarker | biomarkers that complement established staging and Epstein-Barr virus (EBV)-DNA assessment |
PK/PD Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, disease free survival (DFS), overall survival (OS), and toxicity. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | pneumonitis (10 |
Clinical Safety signal | pneumonitis (10 |
Clinical Selected reported efficacy | ORR 47% |
Clinical Reported ORR | 47% |
Clinical Reported PFS | 8 |
Clinical Reported OS | 14 |
Clinical Result source | ClinicalTrials.gov NCT00288054 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00288054 |
추천 비교
추천 비교